Description:

see http://clinicaltrials.gov/ct2/show/record/NCT00617669 Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Link:

http://clinicaltrials.gov/ct2/show/record/NCT00617669

Keywords:
Versions (3) ▾
  1. 11/15/11
  2. 3/23/14
  3. 8/10/14
Uploaded on:

August 10, 2014

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility DRKS00005404 NCT00617669 Prostate Cancer

Eligibility NCT00617669

  1. StudyEvent: Eligibility
    1. Eligibility NCT00617669
Inclusion Criteria
years
male
Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has spread to the bone (bone metastasis)
Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment
Currently receiving treatment with surgical or medical castration
Exclusion Criteria
Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial
Suffering from heart failure or had a myocardial infarction within last 6 months
A history of epilepsy or seizures